My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KraneShares MSCI All China Health Care Index ETF (NY:KURE)

21.44 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KraneShares MSCI All China Health Care Index ETF

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
Via Benzinga
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
Via Benzinga
China Stocks Look Set For A Rebound, Morgan Stanley Quant Strategists Say
Investors in mainland China are rapidly unwinding their stock-index hedges, in an indication that a possible end to Chengdu’s lockdown and policies to stabilize the yuan will lead to a near-term market... 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket. 
Via Benzinga
Topics Government
3 ETFs Thriving in April’s Market Chaos—Are You Missing Out?
These ETFs beat the S&P 500 in April 2025’s turbulent market. Learn how TOLZ, VIXY, and KURE can help stabilize your investment strategy. 
Via MarketBeat
Topics ETFs Economy Stocks
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
China's Market Rebound: Is The NPC Meeting A Turning Point For Investors?
China's NPC meeting has sparked optimism in the market, with Chinese stocks and bonds rallying. Investors are hopeful for growth targets but remain skeptical. 
Via Benzinga
Topics Bonds
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.